Kratom News logo
NIH kratom research grant graphic: $7.5 million over five years to Washington State University to study chronic pain, sleep and kratom risks

An NIH kratom research grant worth $7.5 million has gone to Washington State University, and the timing is hard to miss. The award, announced by WSU on October 26, 2026, funds five years of work on how kratom affects chronic pain, sleep and quality of life. It landed in the same month the Department of Justice confirmed that the Drug Enforcement Administration is moving to place concentrated 7-hydroxymitragynine into Schedule I, with the earliest effective date reported as November 13.

Put plainly: one arm of the federal government is paying to find out what this plant does, while another is drawing lines around which versions of it can legally exist. Both things are true at once, and neither cancels the other out.

$7.5M
NIH award to WSU
5 yrs
Project length
3
Universities involved
1 mg/g
Proposed 7-OH threshold

🔬 What the NIH kratom research grant actually pays for

Infographic showing the two stages of the WSU kratom study: mouse-model work by Arizona and WSU teams, then a human sleep study in chronic low back painWSU describes a two-stage project. First, scientists at the University of Arizona and WSU run studies in mouse models. Then Mary Paine’s group, working with the WSU Sleep and Performance Center, plans a sleep study in people living with chronic low back pain.

The stated aims are narrow and worth quoting accurately. The project will investigate how kratom works, its risks, and its impact on sleep and quality of life for people with chronic pain. WSU says results “will generate critical data to inform the design of future full-scale clinical efficacy trials of kratom.” That is a step toward efficacy research, not a finding about efficacy.

One detail matters more than it might appear. Natural products chemists in North Carolina will select and authenticate the kratom used, stripped of the additives and compounds routinely mixed into retail products. Much of the existing literature is muddied because nobody could say precisely what was in the material being studied. An NIH kratom research grant that starts with a verified botanical removes a variable that has frustrated this field for a decade.

🎓 Who is running it

Mary Paine, a professor in the Department of Pharmaceutical Sciences at WSU’s College of Pharmacy and Pharmaceutical Sciences, leads the project through the Botanical Dietary Supplements Translational Research Team. The collaboration spans WSU’s colleges of Pharmacy, Medicine and Nursing, plus the University of Arizona and the University of North Carolina Greensboro. Paine has prior form here: she has studied how kratom interacts with oxycodone and other medications, work registered as NCT05846451.

Neither WSU nor subsequent coverage named the specific NIH institute behind the award, and no grant number has been published. Those are normal gaps in a press release, but they are gaps, and we will update this piece when the award record is posted.

⚖️ The funder and the regulator sit in the same department

NIH sits inside the Department of Health and Human Services. So does the scientific analysis now driving federal scheduling. On October 9, 2026, DOJ announced updated emergency scheduling actions covering 7-OH and three related compounds: mitragynine pseudoindoxyl (MGPI), MGM-15 and MGM-16. HHS recommended Schedule I control when 7-OH or MGPI alone, or the two combined, exceeds 1 milligram per gram in solid products or 1 milligram per milliliter in liquids, or when the ratio of mitragynine to those compounds falls below 100 to 1.

We have broken down why that is two separate tests rather than one, and why the MGPI threshold was not law on the day it was announced. The short version: HHS framed the thresholds to separate products intentionally enhanced or concentrated in these opioid compounds from material whose alkaloid profile looks like ordinary botanical kratom.

There is a wrinkle for scientists. A temporary scheduling order applies its controls to anyone who handles the substance above the threshold, and the statutory list of covered activities explicitly includes engaging in research. Scheduling does not appear to touch work on kratom leaf, which is what the WSU project uses. It would add a registration burden to anyone studying concentrated 7-OH itself.

“The science has lagged behind and some decisions are being made without having concrete, definitive scientific evidence.”
Mary Paine, WSU, who also said she supports keeping kratom away from minors

🌍 Not the only study in the pipeline

The WSU award is the largest kratom research commitment announced this year, but not the only one. NIH has signaled plans to fund a Phase 1 clinical study of mitragynine as a possible treatment for opioid use disorder. Abroad, Indonesia has agreed to clinical trials aimed at a licensed kratom medicine even while domestic sales stay prohibited, a split that mirrors the American one closely enough to be instructive.

Taken together, that is a research pipeline forming at roughly the same speed as the regulatory one. Whether the data arrives before the rules harden is the open question, and a five-year project answers it slowly by design.

⚠️ What this grant does not say

It does not say kratom works. WSU is explicit that kratom is not approved by the FDA for any medical use, that it is sometimes marketed as an alternative to opioids or a treatment for opioid withdrawal, and that it “comes with overdose and addiction risks of its own.” Paine’s own description of the pharmacology is blunt: at lower doses it behaves like a stimulant, at higher doses like an opioid.

Regular kratom use can produce physical dependence, and stopping after sustained heavy use can cause withdrawal. That risk is not diminished by a research award. If anything, it is part of what the money was granted to measure. Anyone currently using kratom to manage pain should treat the WSU project as a question being asked, not an answer being delivered, and should talk to a clinician rather than to a product label.

❓ Frequently asked questions

How much is the NIH kratom research grant and who received it?

Washington State University announced a $7.5 million grant from the National Institutes of Health on October 26, 2026, funding a five-year project on kratom, chronic pain and sleep. The specific NIH institute and the award number have not been published.

Does the grant mean the government now considers kratom safe or effective?

No. Funding research is not an endorsement. WSU states that kratom is not FDA approved for any medical use and carries overdose and addiction risks. The project is designed to produce data that would inform whether larger efficacy trials are worth running.

Will the 7-OH scheduling action stop this study?

It should not. The proposed federal controls target concentrated 7-hydroxymitragynine and mitragynine pseudoindoxyl above set thresholds, not authenticated kratom leaf, which is the material the WSU team plans to use. Researchers working with concentrated 7-OH above the threshold would face Schedule I registration requirements.

What are the proposed 7-OH thresholds?

HHS recommended Schedule I control when 7-OH or MGPI alone, or combined, exceeds 1 milligram per gram in solids or 1 milligram per milliliter in liquids, or when the ratio of mitragynine to those compounds is less than 100 to 1. A product can fail either test independently.

When will results from the WSU study be available?

The project runs five years and begins with mouse-model work before the human sleep study in people with chronic low back pain. Published findings should not be expected quickly, and the stated goal is to inform the design of future full-scale clinical trials rather than to settle the question itself.

📚 Sources

This article is journalism, not medical advice. Kratom is not approved by the FDA for any medical use. Regular use can lead to physical dependence and withdrawal, and kratom carries overdose and addiction risks. Nothing here is a recommendation to start, stop or change any use of kratom or any medication. Talk to a qualified healthcare professional about your own situation.